Israel Englander Arbutus Biopharma Corp Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Millennium Management LLC holds 250,960 shares of ABUS stock, worth $800,562. This represents 0.0% of its overall portfolio holdings.

Number of Shares

250,960

Previous 208,969 20.09%

Holding current value

$800,562

Previous $645,000 49.77%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $4.56 $131,011 - $191,478	41,991 Added 20.09%	250,960 $966,000
Q2 2024 Aug 14, 2024	SELL	$2.52 - $3.63 $83,772 - $120,672	-33,243 Reduced 13.72%	208,969 $645,000
Q1 2024 May 15, 2024	SELL	$2.26 - $2.92 $2.93 Million - $3.78 Million	-1,295,712 Reduced 84.25%	242,212 $624,000
Q4 2023 Feb 14, 2024	SELL	$1.69 - $2.54 $277,596 - $417,215	-164,258 Reduced 9.65%	1,537,924 $3.84 Million
Q2 2023 Aug 14, 2023	BUY	$2.24 - $3.06 $93,219 - $127,344	41,616 Added 2.51%	1,702,182 $3.92 Million
Q1 2023 May 15, 2023	SELL	$2.23 - $3.1 $428,492 - $595,661	-192,149 Reduced 10.37%	1,660,566 $5.03 Million
Q4 2022 Feb 14, 2023	SELL	$1.91 - $2.85 $3.17 Million - $4.72 Million	-1,657,473 Reduced 47.22%	1,852,715 $4.32 Million
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $1.22 Million - $1.87 Million	-648,876 Reduced 15.6%	3,510,188 $6.7 Million
Q2 2022 Aug 15, 2022	BUY	$1.98 - $3.17 $4.24 Million - $6.79 Million	2,142,740 Added 106.27%	4,159,064 $11.3 Million
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $2.48 Million - $4.07 Million	-1,022,861 Reduced 33.66%	2,016,324 $6.01 Million
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $6.27 Million - $9.3 Million	2,017,490 Added 197.46%	3,039,185 $11.8 Million
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $2.71 Million - $4.72 Million	1,021,695 New	1,021,695 $4.38 Million
Q2 2021 Aug 16, 2021	SELL	$2.5 - $3.51 $1.31 Million - $1.84 Million	-523,263 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$3.14 - $4.84 $1.07 Million - $1.66 Million	342,301 Added 189.16%	523,263 $1.74 Million
Q4 2020 Feb 16, 2021	BUY	$2.76 - $4.97 $499,455 - $899,381	180,962 New	180,962 $642,000
Q3 2020 Nov 16, 2020	SELL	$1.75 - $6.2 $389,502 - $1.38 Million	-222,573 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$0.91 - $2.36 $568,377 - $1.47 Million	-624,591 Reduced 73.73%	222,573 $405,000
Q1 2020 May 14, 2020	BUY	$1.01 - $3.42 $556,699 - $1.89 Million	551,188 Added 186.23%	847,164 $856,000
Q4 2019 Feb 14, 2020	SELL	$0.87 - $2.89 $52,278 - $173,660	-60,090 Reduced 16.88%	295,976 $823,000
Q3 2019 Nov 14, 2019	SELL	$1.34 - $2.4 $221,045 - $395,901	-164,959 Reduced 31.66%	356,066 $543,000
Q2 2019 Aug 15, 2019	BUY	$1.46 - $4.44 $463,802 - $1.41 Million	317,673 Added 156.22%	521,025 $1.08 Million
Q2 2019 Aug 14, 2019	BUY	$1.46 - $4.44 $296,893 - $902,882	203,352 New	203,352 $415,000
Q4 2018 Feb 14, 2019	SELL	$3.5 - $9.66 $108,234 - $298,725	-30,924 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$7.85 - $12.35 $440,895 - $693,637	-56,165 Reduced 64.49%	30,924 $292,000
Q2 2018 Aug 14, 2018	BUY	$5.0 - $7.35 $369,410 - $543,032	73,882 Added 559.42%	87,089 $636,000
Q1 2018 May 15, 2018	SELL	$4.4 - $6.05 $302,720 - $416,240	-68,800 Reduced 83.9%	13,207 $66,000
Q4 2017 Feb 14, 2018	BUY	$4.45 - $7.7 $275,726 - $477,099	61,961 Added 309.09%	82,007 $414,000
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $68,156 - $140,322	20,046	20,046 $124,000

Others Institutions Holding ABUS

# of Institutions

155

Shares Held

99.5M

Call Options Held

2.31M

Put Options Held

525K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $478M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account